Skip to main content
. 2010 Jun 15;103(1):82–89. doi: 10.1038/sj.bjc.6605746

Figure 2.

Figure 2

Expression of cytokeratins (CKs) and vimentin by MDA-MB-231, MCF-7, and MDA-MB-468; and stabilisation of vimentin expression by PlGF. (A) Immunoblots for vimentin, CKs 8/18 and 19 in MDA-MB-231 (lane 1), MCF-7 (lane 2), and MDA-MB-468 (lane 3). Blots were loaded with 10 μg protein per lane, and probed simultaneously for each factor. Actin is from a separate, identical blot. (B) Vimentin expression at 3 h after addition of PlGF (1 nM) or peptide BP-1 (1 μM). Black bars represent vimentin±s.e.m.; white bars, actin±s.e.m. (immunoblot densitometry readings). Vimentin expression increased 1.59±0.33-fold with PlGF treatment, and by 0.97±0.09-fold for PlGF+BP-1 (vs Unt (untreated)±s.d.). Actin variation was 1.04±0.13. *P<0.02 (analysis of variance): n=3 experiments. (C) Vimentin expression following pre-treatment with PlGF before adding actinomycin D (ActD) or CHX vs single-agent treatment (n=2 experiments, each treatment). The table below shows the ratios at 1 and 3 h.